Produktname:5-bromo-2-nitropyridine
IUPAC Name:5-bromo-2-nitropyridine
- CAS：39856-50-3
- Molekulare Formel：C5H3BrN2O2
- Reinheit：95%+
- Katalognummer：CM107933
- Molekulargewicht：203
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:39856-50-3
- Molekulare Formel:C5H3BrN2O2
- Schmelzpunkt:-
- SMILES-Code:O=[N+](C1=NC=C(Br)C=C1)[O-]
- Dichte:
- Katalognummer:CM107933
- Molekulargewicht:203
- Siedepunkt:
- Mdl-Nr.:MFCD00160411
- Lagerung:
Category Infos
- Pyridines
- Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
- Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
- Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
- Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Column Infos
- Ribociclib
- FDA has approved Novartis Kisqali(ribociclib) to reduce risk of recurrence in people with hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR+/HER2-) early breast cancer (EBC).
Kisqali is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Beyond today’s FDA approval of Kisqali for EBC patients in the US, regulatory reviews for Kisqali as an EBC treatment are ongoing worldwide, including in the EU and China.
Suche 
+86 21 5895 0110 
